

David C Smith

List of Publications by Citations

Source: <https://exaly.com/author-pdf/6924861/david-c-smith-publications-by-citations.pdf>

Version: 2024-04-23

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

196
papers

26,599
citations

66
h-index

162
g-index

202
ext. papers

30,570
ext. citations

6
avg, IF

6.5
L-index

#	Paper	IF	Citations
196	Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. <i>New England Journal of Medicine</i> , 2012 , 366, 2443-54	59.2	8684
195	Integrative clinical genomics of advanced prostate cancer. <i>Cell</i> , 2015 , 161, 1215-1228	56.2	1765
194	Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. <i>Journal of Clinical Oncology</i> , 2014 , 32, 1020-30	2.2	1684
193	Overall Survival and Long-Term Safety of Nivolumab (Anti-Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2015 , 33, 2004-12	2.2	859
192	Selected ion flow tube mass spectrometry (SIFT-MS) for on-line trace gas analysis. <i>Mass Spectrometry Reviews</i> , 2005 , 24, 661-700	11	596
191	Personalized oncology through integrative high-throughput sequencing: a pilot study. <i>Science Translational Medicine</i> , 2011 , 3, 111ra121	17.5	452
190	Integrative clinical genomics of metastatic cancer. <i>Nature</i> , 2017 , 548, 297-303	50.4	440
189	Five-Year Follow-Up of Nivolumab in Previously Treated Advanced Non-Small-Cell Lung Cancer: Results From the CA209-003 Study. <i>Journal of Clinical Oncology</i> , 2018 , 36, 1675-1684	2.2	381
188	Cabozantinib in patients with advanced prostate cancer: results of a phase II randomized discontinuation trial. <i>Journal of Clinical Oncology</i> , 2013 , 31, 412-9	2.2	365
187	Survival, Durable Response, and Long-Term Safety in Patients With Previously Treated Advanced Renal Cell Carcinoma Receiving Nivolumab. <i>Journal of Clinical Oncology</i> , 2015 , 33, 2013-20	2.2	337
186	Trastuzumab, paclitaxel, carboplatin, and gemcitabine in advanced human epidermal growth factor receptor-2/neu-positive urothelial carcinoma: results of a multicenter phase II National Cancer Institute trial. <i>Journal of Clinical Oncology</i> , 2007 , 25, 2218-24	2.2	288
185	A longitudinal study of ammonia, acetone and propanol in the exhaled breath of 30 subjects using selected ion flow tube mass spectrometry, SIFT-MS. <i>Physiological Measurement</i> , 2006 , 27, 321-37	2.9	274
184	Phase I trial of radiation dose escalation with concurrent weekly full-dose gemcitabine in patients with advanced pancreatic cancer. <i>Journal of Clinical Oncology</i> , 2001 , 19, 4202-8	2.2	270
183	Quantitative analysis of ammonia on the breath of patients in end-stage renal failure. <i>Kidney International</i> , 1997 , 52, 223-8	9.9	265
182	Progress in SIFT-MS: breath analysis and other applications. <i>Mass Spectrometry Reviews</i> , 2011 , 30, 236-6711		250
181	Randomized clinical trial of a family intervention for prostate cancer patients and their spouses. <i>Cancer</i> , 2007 , 110, 2809-18	6.4	239
180	Phase I, Dose-Escalation, Two-Part Trial of the PARP Inhibitor Talazoparib in Patients with Advanced Germline Mutations and Selected Sporadic Cancers. <i>Cancer Discovery</i> , 2017 , 7, 620-629	24.4	232

179	Five-Year Survival and Correlates Among Patients With Advanced Melanoma, Renal Cell Carcinoma, or Non-Small Cell Lung Cancer Treated With Nivolumab. <i>JAMA Oncology</i> , 2019 , 5, 1411-1420	13.4	216
178	Immune-Modified Response Evaluation Criteria In Solid Tumors (imRECIST): Refining Guidelines to Assess the Clinical Benefit of Cancer Immunotherapy. <i>Journal of Clinical Oncology</i> , 2018 , 36, 850-858	2.2	184
177	Epacadostat Plus Pembrolizumab in Patients With Advanced Solid Tumors: Phase I Results From a Multicenter, Open-Label Phase I/II Trial (ECHO-202/KEYNOTE-037). <i>Journal of Clinical Oncology</i> , 2018 , 36, 3223-3230	2.2	176
176	Recombinant vaccinia-PSA (PROSTVAC) can induce a prostate-specific immune response in androgen-modulated human prostate cancer. <i>Urology</i> , 1999 , 53, 260-6	1.6	175
175	American Society of Clinical Oncology Clinical Practice Guideline on uses of serum tumor markers in adult males with germ cell tumors. <i>Journal of Clinical Oncology</i> , 2010 , 28, 3388-404	2.2	171
174	Time variation of ammonia, acetone, isoprene and ethanol in breath: a quantitative SIFT-MS study over 30 days. <i>Physiological Measurement</i> , 2003 , 24, 107-19	2.9	170
173	Multi-institutional randomized phase II trial of the epothilone B analog ixabepilone (BMS-247550) with or without estramustine phosphate in patients with progressive castrate metastatic prostate cancer. <i>Journal of Clinical Oncology</i> , 2005 , 23, 1439-46	2.2	168
172	Phase 1/2 dose-escalation study of a GM-CSF-secreting, allogeneic, cellular immunotherapy for metastatic hormone-refractory prostate cancer. <i>Cancer</i> , 2008 , 113, 975-84	6.4	166
171	Combination paclitaxel, carboplatin, and gemcitabine is an active treatment for advanced urothelial cancer. <i>Journal of Clinical Oncology</i> , 2001 , 19, 2527-33	2.2	166
170	Living with prostate cancer: patients and spouses psychosocial status and quality of life. <i>Journal of Clinical Oncology</i> , 2007 , 25, 4171-7	2.2	160
169	Analysis of formaldehyde in the headspace of urine from bladder and prostate cancer patients using selected ion flow tube mass spectrometry. <i>Rapid Communications in Mass Spectrometry</i> , 1999 , 13, 1354-9	2.2	147
168	A phase II trial of oral diethylstilbesterol as a second-line hormonal agent in advanced prostate cancer. <i>Urology</i> , 1998 , 52, 257-60	1.6	137
167	Phase II trial of oral estramustine, oral etoposide, and intravenous paclitaxel in hormone-refractory prostate cancer. <i>Journal of Clinical Oncology</i> , 1999 , 17, 1664-71	2.2	137
166	The novel selected-ion flow tube approach to trace gas analysis of air and breath. <i>Rapid Communications in Mass Spectrometry</i> , 1996 , 10, 1183-98	2.2	136
165	Trace gases in breath of healthy volunteers when fasting and after a protein-calorie meal: a preliminary study. <i>Journal of Applied Physiology</i> , 1999 , 87, 1584-8	3.7	130
164	Advances in prostate cancer chemotherapy: a new era begins. <i>Ca-A Cancer Journal for Clinicians</i> , 2005 , 55, 300-18; quiz 323-5	220.7	128
163	Phase II trial of oral 1,25-dihydroxyvitamin D (calcitriol) in hormone refractory prostate cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 1995 , 1, 195-8	2.8	128
162	Repurposing itraconazole as a treatment for advanced prostate cancer: a noncomparative randomized phase II trial in men with metastatic castration-resistant prostate cancer. <i>Oncologist</i> , 2013 , 18, 163-73	5.7	122

161	Small-molecule SMAC mimetics as new cancer therapeutics. <i>Pharmacology & Therapeutics</i> , 2014 , 144, 82-95	13.9	118
160	Application of ion chemistry and the SIFT technique to the quantitative analysis of trace gases in air and on breath. <i>International Reviews in Physical Chemistry</i> , 1996 , 15, 231-271	7	118
159	Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. <i>Journal of Clinical Oncology</i> , 2018 , 36, 991-999	2.2	117
158	Quantification of acetaldehyde released by lung cancer cells in vitro using selected ion flow tube mass spectrometry. <i>Rapid Communications in Mass Spectrometry</i> , 2003 , 17, 845-50	2.2	115
157	A longitudinal study of methanol in the exhaled breath of 30 healthy volunteers using selected ion flow tube mass spectrometry, SIFT-MS. <i>Physiological Measurement</i> , 2006 , 27, 637-48	2.9	111
156	A phase I dose escalation and expansion study of the anticancer stem cell agent demcizumab (anti-DLL4) in patients with previously treated solid tumors. <i>Clinical Cancer Research</i> , 2014 , 20, 6295-303	12.9	110
155	SIFT studies of the reactions of H ₃ O ⁺ , NO ⁺ and O ₂ ⁺ with a series of volatile carboxylic acids and esters. <i>International Journal of Mass Spectrometry and Ion Processes</i> , 1998 , 172, 137-147		110
154	Analysis of breath, exhaled via the mouth and nose, and the air in the oral cavity. <i>Journal of Breath Research</i> , 2008 , 2, 037013	3.1	110
153	Selected ion flow tube mass spectrometry: detection and real-time monitoring of flavours released by food products. <i>Rapid Communications in Mass Spectrometry</i> , 1999 , 13, 585-596	2.2	109
152	Vorinostat in advanced prostate cancer patients progressing on prior chemotherapy (National Cancer Institute Trial 6862): trial results and interleukin-6 analysis: a study by the Department of Defense Prostate Cancer Clinical Trial Consortium and University of Chicago Phase 2 Consortium. <i>Cancer</i> , 2009 , 115, 5511-9	6.4	107
151	A First-in-Human Phase I Study of the Anticancer Stem Cell Agent Ipafricept (OMP-54F28), a Decoy Receptor for Wnt Ligands, in Patients with Advanced Solid Tumors. <i>Clinical Cancer Research</i> , 2017 , 23, 7490-7497	12.9	106
150	A longitudinal study of breath isoprene in healthy volunteers using selected ion flow tube mass spectrometry (SIFT-MS). <i>Physiological Measurement</i> , 2006 , 27, 13-22	2.9	106
149	Cabozantinib in chemotherapy-pretreated metastatic castration-resistant prostate cancer: results of a phase II nonrandomized expansion study. <i>Journal of Clinical Oncology</i> , 2014 , 32, 3391-9	2.2	101
148	Vinflunine in platinum-pretreated patients with locally advanced or metastatic urothelial carcinoma: results of a large phase 2 study. <i>Cancer</i> , 2009 , 115, 4110-7	6.4	101
147	An exploratory comparative study of volatile compounds in exhaled breath and emitted by skin using selected ion flow tube mass spectrometry. <i>Rapid Communications in Mass Spectrometry</i> , 2008 , 22, 526-32	2.2	98
146	Neoadjuvant docetaxel and estramustine chemotherapy in high-risk/locally advanced prostate cancer. <i>Urology</i> , 2003 , 61, 774-80	1.6	98
145	Reactions of Hydrated Hydronium Ions and Hydrated Hydroxide Ions with Some Hydrocarbons and Oxygen-Bearing Organic Molecules. <i>The Journal of Physical Chemistry</i> , 1995 , 99, 15551-15556		98
144	Volatile metabolites in the exhaled breath of healthy volunteers: their levels and distributions. <i>Journal of Breath Research</i> , 2007 , 1, 014004	3.1	91

143	Ambient analysis of trace compounds in gaseous media by SIFT-MS. <i>Analyst, The</i> , 2011 , 136, 2009-32	5	90
142	Enhancement of 1,25-dihydroxyvitamin D3-mediated antitumor activity with dexamethasone. <i>Journal of the National Cancer Institute</i> , 1998 , 90, 134-41	9.7	86
141	Direct, rapid quantitative analyses of BVOCs using SIFT-MS and PTR-MS obviating sample collection. <i>TrAC - Trends in Analytical Chemistry</i> , 2011 , 30, 945-959	14.6	82
140	A randomized phase 2 trial of gemcitabine/cisplatin with or without cetuximab in patients with advanced urothelial carcinoma. <i>Cancer</i> , 2014 , 120, 2684-93	6.4	79
139	Double-blind, randomized, phase 2 trial of maintenance sunitinib versus placebo after response to chemotherapy in patients with advanced urothelial carcinoma. <i>Cancer</i> , 2014 , 120, 692-701	6.4	78
138	A selected ion flow tube mass spectrometry study of ammonia in mouth- and nose-exhaled breath and in the oral cavity. <i>Rapid Communications in Mass Spectrometry</i> , 2008 , 22, 783-9	2.2	78
137	A phase II trial of oral estramustine and oral etoposide in hormone refractory prostate cancer. <i>Urology</i> , 1997 , 50, 401-6; discussion 406-7	1.6	75
136	Acetone, ammonia and hydrogen cyanide in exhaled breath of several volunteers aged 4-83 years. <i>Journal of Breath Research</i> , 2007 , 1, 011001	3.1	71
135	Quantification of breath isoprene using the selected ion flow tube mass spectrometric analytical method. <i>Rapid Communications in Mass Spectrometry</i> , 1999 , 13, 1733-8	2.2	71
134	On-line measurement of the absolute humidity of air, breath and liquid headspace samples by selected ion flow tube mass spectrometry. <i>Rapid Communications in Mass Spectrometry</i> , 2001 , 15, 563-9	2.2	70
133	Phase II study of cilengitide (EMD 121974, NSC 707544) in patients with non-metastatic castration resistant prostate cancer, NCI-6735. A study by the DOD/PCF prostate cancer clinical trials consortium. <i>Investigational New Drugs</i> , 2012 , 30, 749-57	4.3	66
132	Selected ion flow tube studies of the reactions of H ₃ O ⁺ , NO ⁺ , and O ₂ ⁺ with several amines and some other nitrogen-containing molecules. <i>International Journal of Mass Spectrometry</i> , 1998 , 176, 203-219	2.2	66
131	Combined-modality therapy with gemcitabine and radiotherapy as a bladder preservation strategy: results of a phase I trial. <i>Journal of Clinical Oncology</i> , 2004 , 22, 2540-5	2.2	66
130	Influence of water vapour on selected ion flow tube mass spectrometric analyses of trace gases in humid air and breath. <i>Rapid Communications in Mass Spectrometry</i> , 2000 , 14, 1898-906	2.2	65
129	A new online method to measure increased exhaled isoprene in end-stage renal failure. <i>Nephrology Dialysis Transplantation</i> , 2001 , 16, 836-9	4.3	64
128	On-line, simultaneous quantification of ethanol, some metabolites and water vapour in breath following the ingestion of alcohol. <i>Physiological Measurement</i> , 2002 , 23, 477-89	2.9	64
127	Phase II evaluations of cilengitide in asymptomatic patients with androgen-independent prostate cancer: scientific rationale and study design. <i>Clinical Genitourinary Cancer</i> , 2006 , 4, 299-302	3.3	63
126	Testicular Cancer, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2019 , 17, 1529-1554	7.3	62

125	Characterization of bone metastases from rapid autopsies of prostate cancer patients. <i>Clinical Cancer Research</i> , 2011 , 17, 3924-32	12.9	60
124	Genetic counterselective procedure to isolate interspecific cell hybrids containing single human chromosomes: construction of cell hybrids and recombinant DNA libraries specific for human chromosomes 3 and 4. <i>Somatic Cell and Molecular Genetics</i> , 1986 , 12, 163-74		60
123	Concurrent use of H ₃ O ⁺ , NO ⁺ , and O ₂ ⁺ precursor ions for the detection and quantification of diverse trace gases in the presence of air and breath by selected ion-flow tube mass spectrometry. <i>International Journal of Mass Spectrometry</i> , 2001 , 209, 81-97	1.9	59
122	Phase II study of oral bis (aceto) ammine dichloro (cyclohexamine) platinum (IV) (JM-216, BMS-182751) given daily x 5 in hormone refractory prostate cancer (HRPC). <i>Investigational New Drugs</i> , 2005 , 23, 79-84	4.3	58
121	Phase I study of vorinostat (suberoylanilide hydroxamic acid, NSC 701852) in combination with docetaxel in patients with advanced and relapsed solid malignancies. <i>Investigational New Drugs</i> , 2012 , 30, 249-57	4.3	57
120	Combined-modality therapy with gemcitabine and radiation therapy as a bladder preservation strategy: long-term results of a phase I trial. <i>International Journal of Radiation Oncology Biology Physics</i> , 2009 , 74, 511-7	4	55
119	Phase II trial of copper depletion with tetrathiomolybdate as an antiangiogenesis strategy in patients with hormone-refractory prostate cancer. <i>Oncology</i> , 2006 , 71, 168-75	3.6	55
118	A selected ion flow tube (SIFT), study of the reactions of H ₃ O ⁺ , NO ⁺ and O ₂ ⁺ ions with a series of alkenes; in support of SIFT-MS. <i>International Journal of Mass Spectrometry</i> , 2002 , 218, 87-101	1.9	55
117	Reactions of H ₃ O ⁺ and OH ions with some organic molecules; applications to trace gas analysis in air. <i>International Journal of Mass Spectrometry and Ion Processes</i> , 1995 , 145, 177-186		55
116	Combination cisplatin, 5-fluorouracil and radiation therapy for locally advanced unresectable or medically unfit bladder cancer cases: a Southwest Oncology Group Study. <i>Journal of Urology</i> , 2001 , 165, 56-60; discussion 60-1	2.5	54
115	A sequential treatment approach to myoinvasive urothelial cancer: a phase II Southwest Oncology Group trial (S0219). <i>Journal of Urology</i> , 2009 , 181, 2476-80; discussion 2480-1	2.5	53
114	Quantitative selected ion flow tube mass spectrometry: the influence of ionic diffusion and mass discrimination. <i>Journal of the American Society for Mass Spectrometry</i> , 2001 , 12, 863-72	3.5	53
113	Selected ion flow tube mass spectrometry of urine headspace. <i>Rapid Communications in Mass Spectrometry</i> , 1999 , 13, 724-9	2.2	52
112	Phase II randomised discontinuation trial of cabozantinib in patients with advanced solid tumours. <i>European Journal of Cancer</i> , 2017 , 86, 296-304	7.5	51
111	First-in-human multicenter phase I study of BMS-936561 (MDX-1203), an antibody-drug conjugate targeting CD70. <i>Cancer Chemotherapy and Pharmacology</i> , 2016 , 77, 155-62	3.5	50
110	Breath analysis of ammonia, volatile organic compounds and deuterated water vapor in chronic kidney disease and during dialysis. <i>Bioanalysis</i> , 2014 , 6, 843-57	2.1	50
109	Safety, pharmacokinetics, and pharmacodynamic properties of oral DEBIO1143 (AT-406) in patients with advanced cancer: results of a first-in-man study. <i>Cancer Chemotherapy and Pharmacology</i> , 2015 , 75, 851-9	3.5	46
108	A phase II trial of all-trans-retinoic acid in hormone-refractory prostate cancer: a clinical trial with detailed pharmacokinetic analysis. <i>Cancer Chemotherapy and Pharmacology</i> , 1997 , 39, 349-56	3.5	46

107	Phase II trial of paclitaxel, carboplatin and gemcitabine in patients with locally advanced carcinoma of the bladder. <i>Journal of Urology</i> , 2008 , 180, 2384-8; discussion 2388	2.5	45
106	Cilengitide (EMD 121974, NSC 707544) in asymptomatic metastatic castration resistant prostate cancer patients: a randomized phase II trial by the prostate cancer clinical trials consortium. <i>Investigational New Drugs</i> , 2011 , 29, 1432-40	4.3	44
105	Selected ion flow tube studies of the reactions of H ₃ O ⁺ , NO ⁺ , and O ₂ ⁺ with several aromatic and aliphatic monosubstituted halocarbons. <i>International Journal of Mass Spectrometry</i> , 1999 , 189, 213-223	1.9	44
104	The concentration distributions of some metabolites in the exhaled breath of young adults. <i>Journal of Breath Research</i> , 2007 , 1, 026001	3.1	40
103	Increase of acetone and ammonia in urine headspace and breath during ovulation quantified using selected ion flow tube mass spectrometry. <i>Physiological Measurement</i> , 2003 , 24, 191-9	2.9	39
102	Analysis of petrol and diesel vapour and vehicle engine exhaust gases using selected ion flow tube mass spectrometry. <i>Rapid Communications in Mass Spectrometry</i> , 2002 , 16, 1124-34	2.2	38
101	Nivolumab (anti-PD-1; BMS-936558; ONO-4538) in patients with advanced solid tumors: Survival and long-term safety in a phase I trial.. <i>Journal of Clinical Oncology</i> , 2013 , 31, 3002-3002	2.2	38
100	Generation of volatile compounds on mouth exposure to urea and sucrose: implications for exhaled breath analysis. <i>Physiological Measurement</i> , 2006 , 27, N7-17	2.9	37
99	A selected ion flow tube study of the reactions of H ₃ O ⁺ , NO ⁺ and O ₂ ⁺ with some phenols, phenyl alcohols and cyclic carbonyl compounds in support of SIFT-MS and PTR-MS. <i>International Journal of Mass Spectrometry</i> , 2004 , 239, 139-146	1.9	37
98	A first-in-human phase 1a study of the bispecific anti-DLL4/anti-VEGF antibody navicixizumab (OMP-305B83) in patients with previously treated solid tumors. <i>Investigational New Drugs</i> , 2019 , 37, 461-472	4.3	37
97	Rapid, ultra low coverage copy number profiling of cell-free DNA as a precision oncology screening strategy. <i>Oncotarget</i> , 2017 , 8, 89848-89866	3.3	36
96	The Selected Ion Flow Tube Method for Workplace Analyses of Trace Gases in Air and Breath: Its Scope, Validation, and Applications. <i>Journal of Occupational and Environmental Hygiene</i> , 1998 , 13, 817-823		36
95	A phase 1 trial of SGN-CD70A in patients with CD70-positive diffuse large B cell lymphoma and mantle cell lymphoma. <i>Investigational New Drugs</i> , 2019 , 37, 297-306	4.3	35
94	Efficient delivery of radical cystectomy after neoadjuvant chemotherapy for muscle-invasive bladder cancer: a multidisciplinary approach. <i>Cancer</i> , 2012 , 118, 44-53	6.4	35
93	Quantification of volatile compounds in the headspace of aqueous liquids using selected ion flow tube mass spectrometry. <i>Rapid Communications in Mass Spectrometry</i> , 2002 , 16, 2148-53	2.2	35
92	First-In-Human Phase I Study Of A Dual mTOR Kinase And DNA-PK Inhibitor (CC-115) In Advanced Malignancy. <i>Cancer Management and Research</i> , 2019 , 11, 10463-10476	3.6	35
91	Volatile compounds in health and disease. <i>Current Opinion in Clinical Nutrition and Metabolic Care</i> , 2011 , 14, 455-60	3.8	33
90	Phase 1 study of ixazomib, an investigational proteasome inhibitor, in advanced non-hematologic malignancies. <i>Investigational New Drugs</i> , 2015 , 33, 652-63	4.3	32

89	SIFT-MS and FA-MS methods for ambient gas phase analysis: developments and applications in the UK. <i>Analyst, The</i> , 2015 , 140, 2573-91	5	32
88	Effects of cabozantinib on pain and narcotic use in patients with castration-resistant prostate cancer: results from a phase 2 nonrandomized expansion cohort. <i>European Urology</i> , 2015 , 67, 310-8	10.2	32
87	Population pharmacokinetics of hydroxyurea in cancer patients. <i>Cancer Chemotherapy and Pharmacology</i> , 1995 , 35, 417-22	3.5	31
86	Phase I study of ixabepilone, mitoxantrone, and prednisone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel-based therapy: a study of the department of defense prostate cancer clinical trials consortium. <i>Journal of Clinical Oncology</i> , 2009 , 27, 2772-8	2.2	30
85	Phase II trial of oral cyclophosphamide, prednisone, and diethylstilbestrol for androgen-independent prostate carcinoma. <i>Cancer</i> , 2003 , 98, 1603-10	6.4	30
84	Association between Agent Orange and prostate cancer: a pilot case-control study. <i>Urology</i> , 2004 , 63, 757-60; discussion 760-1	1.6	30
83	Development of 2 Bromodomain and Extraterminal Inhibitors With Distinct Pharmacokinetic and Pharmacodynamic Profiles for the Treatment of Advanced Malignancies. <i>Clinical Cancer Research</i> , 2020 , 26, 1247-1257	12.9	29
82	Prospective quality-of-life assessment in patients receiving concurrent gemcitabine and radiotherapy as a bladder preservation strategy. <i>Urology</i> , 2004 , 64, 69-73	1.6	29
81	Randomized, double-blind, placebo-controlled phase II trial of maintenance sunitinib versus placebo after chemotherapy for patients with advanced urothelial carcinoma: scientific rationale and study design. <i>Clinical Genitourinary Cancer</i> , 2007 , 5, 460-3	3.3	28
80	Selected ion flow tube studies of the reactions of H ₃ O ⁺ , NO ⁺ , and O ₂ ⁺ with eleven amine structural isomers of c ₅ H ₁₃ N. <i>International Journal of Mass Spectrometry</i> , 1999 , 185-187, 139-147	1.9	28
79	Phase II trial of paclitaxel, estramustine, etoposide, and carboplatin in the treatment of patients with hormone-refractory prostate carcinoma. <i>Cancer</i> , 2003 , 98, 269-76	6.4	27
78	Expression of nuclear antigen Ki-67 in prostate cancer needle biopsy and radical prostatectomy specimens. <i>Journal of the National Cancer Institute</i> , 2000 , 92, 1941-2	9.7	27
77	A phase II trial of neoadjuvant nab-paclitaxel, carboplatin, and gemcitabine (ACaG) in patients with locally advanced carcinoma of the bladder. <i>Urology</i> , 2013 , 82, 111-7	1.6	26
76	A selected ion flow tube, SIFT, study of the reactions of H ₃ O ⁺ , NO ⁺ and O ₂ ⁺ ions with a series of diols. <i>International Journal of Mass Spectrometry</i> , 2002 , 218, 227-236	1.9	26
75	Megestrol acetate in the treatment of hormone refractory prostate cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 1997 , 20, 308-10	2.7	26
74	Multigene Profiling of CTCs in mCRPC Identifies a Clinically Relevant Prognostic Signature. <i>Molecular Cancer Research</i> , 2018 , 16, 643-654	6.6	24
73	The quantification of carbon dioxide in humid air and exhaled breath by selected ion flow tube mass spectrometry. <i>Rapid Communications in Mass Spectrometry</i> , 2009 , 23, 1419-25	2.2	24
72	Kinetics and isotope patterns of ethanol and acetaldehyde emissions from yeast fermentations of glucose and glucose-6,6-d ₂ using selected ion flow tube mass spectrometry: a case study. <i>Rapid Communications in Mass Spectrometry</i> , 2002 , 16, 69-76	2.2	24

71	Chemotherapy for hormone refractory prostate cancer. <i>Urologic Clinics of North America</i> , 1999 , 26, 323-319	24
70	A SIFT study of the reactions of H ₂ ONO ⁺ ions with several types of organic molecules. <i>International Journal of Mass Spectrometry</i> , 2003 , 230, 1-9	1.9 23
69	Course of distress and quality of life in testicular cancer patients before, during, and after chemotherapy: results of a pilot study. <i>Psycho-Oncology</i> , 2003 , 12, 814-20	3.9 23
68	Phase II trial of suramin in patients with metastatic renal cell carcinoma. <i>Investigational New Drugs</i> , 1999 , 17, 183-6	4.3 23
67	On-line analysis of diesel engine exhaust gases by selected ion flow tube mass spectrometry. <i>Rapid Communications in Mass Spectrometry</i> , 2004 , 18, 2830-8	2.2 22
66	TRANSFORMER: A Randomized Phase II Study Comparing Bipolar Androgen Therapy Versus Enzalutamide in Asymptomatic Men With Castration-Resistant Metastatic Prostate Cancer. <i>Journal of Clinical Oncology</i> , 2021 , 39, 1371-1382	2.2 22
65	A randomized phase II study of cediranib alone versus cediranib in combination with dasatinib in docetaxel resistant, castration resistant prostate cancer patients. <i>Investigational New Drugs</i> , 2014 , 32, 1005-16	4.3 21
64	Pharmacokinetic and biotransformation studies of ormaplatin in conjunction with a phase I clinical trial. <i>Cancer Chemotherapy and Pharmacology</i> , 1994 , 33, 347-54	3.5 21
63	A phase 2 randomised discontinuation trial of cabozantinib in patients with ovarian carcinoma. <i>European Journal of Cancer</i> , 2017 , 83, 229-236	7.5 20
62	On the features, successes and challenges of selected ion flow tube mass spectrometry. <i>European Journal of Mass Spectrometry</i> , 2013 , 19, 225-46	1.1 20
61	Quantification of volatile metabolites in exhaled breath by selected ion flow tube mass spectrometry, SIFT-MS. <i>Clinical Mass Spectrometry</i> , 2020 , 16, 18-24	1.9 19
60	What is the real utility of breath ammonia concentration measurements in medicine and physiology?. <i>Journal of Breath Research</i> , 2018 , 12, 027102	3.1 19
59	Mechanistic Support for Combined MET and AR Blockade in Castration-Resistant Prostate Cancer. <i>Neoplasia</i> , 2016 , 18, 1-9	6.4 19
58	Phase I study evaluating the combination of lapatinib (a Her2/Neu and EGFR inhibitor) and everolimus (an mTOR inhibitor) in patients with advanced cancers: South West Oncology Group (SWOG) Study S0528. <i>Cancer Chemotherapy and Pharmacology</i> , 2013 , 72, 1089-96	3.5 19
57	Change in markers of bone metabolism with chemotherapy for advanced prostate cancer: interleukin-6 response is a potential early indicator of response to therapy. <i>Journal of Interferon and Cytokine Research</i> , 2009 , 29, 105-12	3.5 19
56	All-trans-retinoic acid modulation of drug-metabolizing enzyme activities: investigation with selective metabolic drug probes. <i>Cancer Chemotherapy and Pharmacology</i> , 1998 , 41, 133-9	3.5 19
55	Treatment of biochemical recurrence of prostate cancer with granulocyte-macrophage colony-stimulating factor secreting, allogeneic, cellular immunotherapy. <i>Journal of Urology</i> , 2008 , 180, 2011-7; discussion 2017-8	2.5 19
54	A phase 1 study of nevanimibe HCl, a novel adrenal-specific sterol O-acyltransferase 1 (SOAT1) inhibitor, in adrenocortical carcinoma. <i>Investigational New Drugs</i> , 2020 , 38, 1421-1429	4.3 19

53	Assessment of Clinical Benefit of Integrative Genomic Profiling in Advanced Solid Tumors. <i>JAMA Oncology</i> , 2021 , 7, 525-533	13.4	19
52	Adjuvant and neoadjuvant therapy in prostate cancer. <i>Seminars in Oncology</i> , 2001 , 28, 3-12	5.5	18
51	A new concept in cancer care: the supportive care program. <i>American Journal of Hospice and Palliative Medicine</i> , 1999 , 16, 713-22	2.6	18
50	A phase I trial of high-dose oral tamoxifen and CHOPE. <i>Cancer Chemotherapy and Pharmacology</i> , 1995 , 36, 65-8	3.5	18
49	Phase 1 study of mTORC1/2 inhibitor sapanisertib (TAK-228) in advanced solid tumours, with an expansion phase in renal, endometrial or bladder cancer. <i>British Journal of Cancer</i> , 2020 , 123, 1590-1598	8.7	17
48	Phase 1 study of single-agent WNT974, a first-in-class Porcupine inhibitor, in patients with advanced solid tumours. <i>British Journal of Cancer</i> , 2021 , 125, 28-37	8.7	17
47	Selected ion flow tube studies of the reactions of H ₃ O ⁺ , NO ⁺ and O ₂ ⁺ with the anaesthetic gases halothane, isoflurane and sevoflurane. <i>Rapid Communications in Mass Spectrometry</i> , 2002 , 16, 1860-70	2.2	16
46	An investigation of the reactions of H ₃ O ⁺ and O ₂ ⁺ with NO, NO ₂ , N ₂ O and HNO ₂ in support of selected ion flow tube mass spectrometry. <i>Rapid Communications in Mass Spectrometry</i> , 2000 , 14, 646-51	2.2	16
45	Streamlining Adverse Events Reporting in Oncology: An American Society of Clinical Oncology Research Statement. <i>Journal of Clinical Oncology</i> , 2018 , 36, 617-623	2.2	16
44	A phase I open-label trial evaluating the cardiovascular safety of regorafenib in patients with advanced cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2015 , 76, 777-84	3.5	14
43	On the importance of accurate quantification of individual volatile metabolites in exhaled breath. <i>Journal of Breath Research</i> , 2017 , 11, 047106	3.1	13
42	Phase II evaluation of early oral estramustine, oral etoposide, and intravenous paclitaxel combined with hormonal therapy in patients with high-risk metastatic prostate adenocarcinoma: Southwest Oncology Group S0032. <i>Urology</i> , 2011 , 77, 1172-6	1.6	12
41	Novel gemcitabine-containing triplets in the management of urothelial cancer. <i>Seminars in Oncology</i> , 2002 , 29, 20-4	5.5	12
40	Phase I study of MEDI0639 in patients with advanced solid tumors.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 3024-3024	2.2	12
39	Ixabepilone, mitoxantrone, and prednisone for metastatic castration-resistant prostate cancer after docetaxel-based therapy: a phase 2 study of the Department Of Defense Prostate Cancer Clinical Trials Consortium. <i>Cancer</i> , 2011 , 117, 2419-25	6.4	11
38	Phase II trial of oral uracil/tegafur plus leucovorin in patients with hormone-refractory prostate carcinoma. <i>Cancer</i> , 2006 , 106, 1715-21	6.4	10
37	Lack of pharmacokinetic drug-drug interaction between ramucirumab and paclitaxel in a phase II study of patients with advanced malignant solid tumors. <i>Cancer Chemotherapy and Pharmacology</i> , 2016 , 78, 433-41	3.5	10
36	Melanoma and immunotherapy bridge 2015 : Naples, Italy. 1-5 December 2015. <i>Journal of Translational Medicine</i> , 2016 , 14, 65	8.5	8

35	A phase I trial of high-dose continuous-infusion hydroxyurea. <i>Cancer Chemotherapy and Pharmacology</i> , 1993 , 33, 139-43	3.5	8
34	Phase II trial of combination nab-paclitaxel, carboplatin and gemcitabine in first line therapy of advanced urothelial carcinoma. <i>Investigational New Drugs</i> , 2014 , 32, 188-94	4.3	7
33	The use of prostate-specific antigen as a surrogate end point in the treatment of patients with hormone refractory prostate cancer. <i>Urologic Clinics of North America</i> , 1997 , 24, 433-7	2.9	7
32	Phase II evaluation of oral estramustine, oral etoposide, and intravenous paclitaxel in patients with hormone-sensitive prostate adenocarcinoma. <i>Clinical Genitourinary Cancer</i> , 2007 , 5, 318-22	3.3	7
31	Phase I and pharmacokinetic study of vinblastine and high-dose megestrol acetate. <i>Cancer Chemotherapy and Pharmacology</i> , 2002 , 50, 179-85	3.5	7
30	The use of preferences to measure the benefit of adjuvant radiation therapy for stage I seminoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2002 , 53, 934-41	4	7
29	Recent SIFT-MS Studies of Volatile Compounds in Physiology, Medicine and Cell Biology 2013 , 48-76		6
28	The increase of breath ammonia induced by niacin ingestion quantified by selected ion flow tube mass spectrometry. <i>Physiological Measurement</i> , 2006 , 27, 437-44	2.9	6
27	Chemotherapy in patients with prostate specific antigen-only disease after primary therapy for prostate carcinoma: a phase II trial of oral estramustine and oral etoposide. <i>Cancer</i> , 2001 , 91, 2175-80	6.4	6
26	A phase II trial of CI-958 in patients with hormone-refractory prostate cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 1999 , 44, 511-7	3.5	6
25	Phase I study of BCNU and intravenous 6-mercaptopurine in patients with anaplastic gliomas. <i>Cancer Chemotherapy and Pharmacology</i> , 1992 , 30, 272-6	3.5	6
24	Cardiovascular and Metabolic Toxicity of Abiraterone in Castration-resistant Prostate Cancer: Post-marketing Experience. <i>Clinical Genitourinary Cancer</i> , 2019 , 17, e592-e601	3.3	5
23	Oral chemotherapy for hormone refractory prostate cancer. The University of Michigan experience. <i>Urologic Clinics of North America</i> , 1999 , 26, 333-40	2.9	5
22	Clinical activity and safety of anti-PD-1 (BMS-936558, MDX-1106) in patients with previously treated metastatic renal cell carcinoma (mRCC).. <i>Journal of Clinical Oncology</i> , 2012 , 30, 4505-4505	2.2	5
21	Reagent and analyte ion hydrates in secondary electrospray ionization mass spectrometry (SESI-MS), their equilibrium distributions and dehydration in an ion transfer capillary: Modelling and experiments. <i>Rapid Communications in Mass Spectrometry</i> , 2021 , 35, e9047	2.2	5
20	A phase 2 trial of salvage radiation and concurrent weekly docetaxel after a rising prostate-specific antigen level after radical prostatectomy. <i>Advances in Radiation Oncology</i> , 2016 , 1, 59-66	3.3	4
19	Dose escalation of oral vinorelbine in combination with estramustine in hormone-refractory adenocarcinoma of the prostate. <i>Cancer</i> , 2006 , 106, 2617-23	6.4	4
18	Oral chemotherapy in the treatment of hormone-refractory prostate cancer. <i>Drugs</i> , 1999 , 58 Suppl 3, 127-31	12.1	4

17	Phase II trial and pharmacokinetic assessment of intravenous melphalan in patients with advanced prostate cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 1993 , 31, 363-8	3.5	4
16	Phase 1 extension study of BBI503, a first-in-class cancer stemness kinase inhibitor, in patients with advanced colorectal cancer.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 3615-3615	2.2	4
15	Detailed pathologic analysis on the co-occurrence of non-seminomatous germ cell tumor subtypes in matched orchiectomy and retroperitoneal lymph node dissections. <i>Medical Oncology</i> , 2018 , 35, 21	3.7	3
14	Evaluation of the effect of necitumumab on the corrected QT interval in patients with advanced solid tumors. <i>Cancer Chemotherapy and Pharmacology</i> , 2016 , 78, 271-80	3.5	2
13	Electrocardiographic Characterization of Ramucirumab on the Corrected QT Interval in a Phase II Study of Patients With Advanced Solid Tumors. <i>Oncologist</i> , 2016 , 21, 402-3	5.7	2
12	Chemotherapy for localized, high-risk prostate cancer. <i>Seminars in Radiation Oncology</i> , 2003 , 13, 152-157	5.5	2
11	Phase II study evaluating the effect of concomitant ramucirumab (IMC-1121B; RAM) on the pharmacokinetics (PK) of docetaxel (DOC) in patients (pts) with advanced malignant solid tumors.. <i>Journal of Clinical Oncology</i> , 2014 , 32, e13539-e13539	2.2	2
10	Multimodal imaging provides insight into targeted therapy response in metastatic prostate cancer to the bone. <i>American Journal of Nuclear Medicine and Molecular Imaging</i> , 2018 , 8, 189-199	2.2	2
9	Clinical impact of high-throughput sequencing in patients with advanced cancer: Lessons learned from the Michigan Oncology Sequencing Center.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 11057-11057	2.2	1
8	Efficacy and Effect of Cabozantinib on Bone Metastases in Treatment-naïve Castration-resistant Prostate Cancer. <i>Clinical Genitourinary Cancer</i> , 2020 , 18, 332-339.e2	3.3	1
7	CD38 in Advanced Prostate Cancers. <i>European Urology</i> , 2021 , 79, 736-746	10.2	0
6	Academic Cancer Center Phase I Program Development. <i>Oncologist</i> , 2017 , 22, 369-374	5.7	
5	A phase I trial of high-dose oral tamoxifen and CHOPE. <i>Cancer Chemotherapy and Pharmacology</i> , 1995 , 36, 65-68	3.5	
4	Phase I dose-escalation study with extended daily administration of Debio1143, an oral inhibitor of apoptosis protein inhibitor, in patients with solid tumors.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 2531-2537	2.2	
3	Targeting C-Met/VEGF in Castration Resistant Prostate Cancer. <i>Current Clinical Urology</i> , 2014 , 265-276		
2	ABLE: Phase 2, single-arm, two-stage study of nabpaclitaxel with anti-PD1/PDL1 in advanced urothelial cancer.. <i>Journal of Clinical Oncology</i> , 2022 , 40, 502-502	2.2	
1	Pharmacokinetic and biotransformation studies of ormaplatin in conjunction with a phase I clinical trial. <i>Cancer Chemotherapy and Pharmacology</i> , 1994 , 33, 347-354	3.5	